Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) recently announced disappointing top-line data from the final phase III study evaluating Nuvigil (armodafinil) as adjunct therapy in adults with major depression associated with bipolar I disorder.

Although results showed that Nuvigil achieved statistical significance in several important secondary endpoints (like responder rate and remission), it failed to achieve the primary endpoint. The primary endpoint was to see whether Nuvigil (150mg per day) was more effective compared to placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics.

Nuvigil is currently approved for the improvement of wakefulness in adults who experience excessive sleepiness due to obstructive sleep apnea, shift work disorder, or narcolepsy. Nuvigil sales were $157 million in the first half of 2013. Teva was looking to drive sales by expanding the label into additional indications. However, based on the final phase III study results, Teva has decided that it will not go ahead with regulatory filings for expanding Nuvigil’s label for the treatment of major depression associated with bipolar I disorder.

Teva currently carries a Zacks Rank #3 (Hold). The company is going through a tough transition period given fewer large generic opportunities, potential new competition for branded products (especially Copaxone) and a higher cost base.

However, we are encouraged by Teva’s plans to improve its position. Teva said that it intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. We expect investor focus to remain on the execution of the company’s new strategy.

At present, companies like Actavis, Inc. (ACT - Analyst Report), AxoGen, Inc. (AXGN - Snapshot Report) and Akorn, Inc. (AKRX - Snapshot Report) look well-positioned with all three being Zacks Rank #2 (Buy) stocks.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%